Malignant phyllodes tumours of the breast: the case for revising WHO's 'full house' diagnostic criteria.

TitleMalignant phyllodes tumours of the breast: the case for revising WHO's 'full house' diagnostic criteria.
Publication TypeJournal Article
Year of Publication2025
AuthorsTan PHoon, Ellis IO, Allison KH, Badve SS, Brogi E, Callagy G, Charafe-Jauffret E, Chen C-J, Chen Y-Y, Collins LC, Cserni G, Djerroudi L, Foschini MPia, Fox SB, Gobbi H, Gudi M, Harada O, Jaffer S, Kulka J, Kuroda H, Lakhani SR, Li X, Moriya T, O'Toole S, Pinder SE, Provenzano E, Quinn C, Raymond W, Sahin AA, Schmitt F, Shaaban AM, Shet T, Siziopikou KP, Tang P, Tse GM, Varga Z, Vincent-Salomon A, Wen H, Yamaguchi R, Yang W, Schnitt SJ, Rakha EA
JournalHistopathology
Date Published2025 Apr 13
ISSN1365-2559
Abstract

Phyllodes tumours (PTs) of the breast present diagnostic challenges due to their complex histological features and potential for malignant behaviour. The World Health Organisation (WHO) classification requires the presence of five adverse histological criteria to categorise PTs as malignant, aiming to avoid overdiagnosis and improve diagnostic consistency. However, emerging evidence suggests that these strict criteria may underdiagnose tumours with metastatic potential and histological features that would otherwise be considered malignant in soft tissue tumours, leading to significant implications for prognosis and treatment. Recent studies have highlighted cases where tumours classified as borderline PT by WHO criteria exhibited metastatic behaviour, emphasising the need to refine the diagnostic framework. Microscopic criteria used to classify PT also vary among reporting pathologists, resulting in suboptimal reproducibility. This review examines the histological parameters utilised in the classification of malignant PT, highlights existing evidence gaps and analyses international breast pathologist survey data to propose a pragmatic diagnostic approach. We recommend redefining malignant PTs to include cases meeting four of the five WHO criteria, supplemented by comprehensive sampling and clinical context. This approach balances the risk of underdiagnosis with the need for standardised, reproducible diagnostic practices. Future collaborative efforts should focus upon developing evidence-based, biologically relevant classification systems and leveraging technological advancements to enhance diagnostic precision. These efforts aim to refine classification, improve prognostic accuracy and optimise patient management strategies.

DOI10.1111/his.15455
Alternate JournalHistopathology
PubMed ID40223225
Related Faculty: 
Laura C. Collins, MBBS

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700